Most Read

Three drugmakers are part of the COVID R&D Alliance, which was established in March this year to boost the study candidates without regard to company affiliation. The alliance,

The mRNA-1273 is an mRNA vaccine against Covid-19 encoding for a prefusion stabilised form of the Spike (S) protein. It was co-developed by Moderna and investigators from NIAID’s

The company-sponsored study is being carried out in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and

CF, a rare and life-shortening genetic disease, that affects around 75,000 people across the globe. It is a progressive and multi-system disease that damages the lungs, liver, GI

1n 2019, Astellas and FibroGen have also received Japanese approval for roxadustat for the treatment of anaemia in adult patients with CKD and on dialysis. FibroGen now secures

City of Hope will assess the investigational vaccine, dubbed COH04S1, in healthy volunteers aged between 18 and 55 who have not had Covid-19. The investigational vaccine is being

Under the deal, OncoImmune shareholders will be eligible to secure sales-based payments and payments contingent on the achievement of certain regulatory milestones. Recently, the biopharmaceutical company announced positive

The high-level results from an interim analysis, including 131 Covid-19, have shown no hospitalisations or severe cases of the disease in participants receiving the vaccine. AZD1222, co-invented by

The companies have submitted a request to the FDA to secure FDA EUA status for BNT162b2 mRNA vaccine candidate against SARS-CoV-2. The Covid-19 vaccine is expected to be